The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species

• Main Authors: Jessica Basso (Author), Kuan-Ju Chen (Author), Yuchen Zhou (Author), Lilly Mark (Author), Daniel LaSala (Author), Arielle Dorfman (Author), Mary Atalla (Author), Donald Chun (Author), Veronica Viramontes (Author), Christina Chang (Author), Franziska Leifer (Author), Patrick P. McDonald (Author), David C. Cipolla (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Brensocatib is a novel, oral, selective, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which activates several neutrophil serine proteases (NSPs), including neutrophil elastase (NE), proteinase 3 (PR3), and cathepsin G (CatG) in the bone marrow during the early stage of neutrophil maturatio...